WallStSmart

HCA Healthcare, Inc. (HCA)vsNewGenIvf Group Limited Class A Ordinary Shares (NIVF)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

HCA Healthcare, Inc. generates 1650480% more annual revenue ($78.01B vs $4.73M). NIVF leads profitability with a 209.0% profit margin vs 8.8%. HCA earns a higher WallStSmart Score of 65/100 (C+).

HCA

Buy

65

out of 100

Grade: C+

Growth: 6.0Profit: 8.0Value: 5.3Quality: 6.0
Piotroski: 5/9Altman Z: 1.71

NIVF

Buy

57

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 5.0Quality: 9.0
Piotroski: 4/9Altman Z: 4.07
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

HCASignificantly Overvalued (-76.5%)

Margin of Safety

-76.5%

Fair Value

$301.11

Current Price

$426.94

$125.83 premium

UndervaluedFair: $301.11Overvalued

Intrinsic value data unavailable for NIVF.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HCA5 strengths · Avg: 9.0/10
Return on EquityProfitability
136.3%10/10

Every $100 of equity generates 136 in profit

Debt/EquityHealth
-7.4210/10

Conservative balance sheet, low leverage

Market CapQuality
$92.43B9/10

Large-cap with strong market position

P/E RatioValuation
14.3x8/10

Attractively priced relative to earnings

Free Cash FlowQuality
$1.10B8/10

Generating 1.1B in free cash flow

NIVF5 strengths · Avg: 9.8/10
Price/BookValuation
0.0x10/10

Reasonable price relative to book value

Return on EquityProfitability
79.4%10/10

Every $100 of equity generates 79 in profit

Profit MarginProfitability
209.0%10/10

Keeps 209 of every $100 in revenue as profit

Altman Z-ScoreHealth
4.0710/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.189/10

Conservative balance sheet, low leverage

Areas to Watch

HCA1 concerns · Avg: 4.0/10
Altman Z-ScoreHealth
1.714/10

Distress zone — elevated risk

NIVF3 concerns · Avg: 2.7/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$2.43M3/10

Smaller company, higher risk/reward

Operating MarginProfitability
-349.1%1/10

Operating margin of -349.1%

Comparative Analysis Report

WallStSmart Research

Bull Case : HCA

The strongest argument for HCA centers on Return on Equity, Debt/Equity, Market Cap. PEG of 1.29 suggests the stock is reasonably priced for its growth.

Bull Case : NIVF

The strongest argument for NIVF centers on Price/Book, Return on Equity, Profit Margin. Profitability is solid with margins at 209.0% and operating margin at -349.1%. Revenue growth of 11.9% demonstrates continued momentum.

Bear Case : HCA

The primary concerns for HCA are Altman Z-Score.

Bear Case : NIVF

The primary concerns for NIVF are EPS Growth, Market Cap, Operating Margin.

Key Dynamics to Monitor

HCA profiles as a value stock while NIVF is a mature play — different risk/reward profiles.

HCA carries more volatility with a beta of 1.11 — expect wider price swings.

NIVF is growing revenue faster at 11.9% — sustainability is the question.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

HCA scores higher overall (65/100 vs 57/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

HCA Healthcare, Inc.

HEALTHCARE · MEDICAL CARE FACILITIES · USA

HCA Healthcare is an American for-profit operator of health care facilities that was founded in 1968. It is based in Nashville, Tennessee, and, as of May 2020, owns and operates 186 hospitals and approximately 2,000 sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics in 21 states and the United Kingdom.

Visit Website →

NewGenIvf Group Limited Class A Ordinary Shares

HEALTHCARE · MEDICAL CARE FACILITIES · USA

NewGenIvf Group Limited (NIVF) is a pioneering organization in the reproductive health industry, specializing in innovative fertility solutions, including advanced in vitro fertilization (IVF) services. The company is dedicated to enhancing success rates in assisted reproductive technologies and is strategically positioned to capitalize on the growing global demand for fertility treatments, supported by a robust network of clinics and strategic partnerships. As the fertility services market continues to expand, NIVF is well-equipped for substantial growth, with a mission to assist individuals and couples in their journey to parenthood through forward-thinking healthcare solutions.

Want to dig deeper into these stocks?